News
BHVN
--
0.00%
--
DJ Biohaven Pharmaceutical Shares Drop After Troriluzole Trial
Dow Jones · 9h ago
Biohaven Dives After Experimental Alzheimer's Treatment Flops In Key Test
Investor's Business Daily · 11h ago
Biohaven Shares Fall 8% in Wake of Phase II/III Study for Drug Candidate Troriluzole in Treatment of Alzheimer's
MT Newswires · 11h ago
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
Zacks · 12h ago
Biohaven's troriluzole unsuccessful in Alzheimer's study
Biohaven Pharmaceutical (BHVN) drops 15% premarket in reaction to topline data from Phase 2/3 trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease. The study showed that the treatment failed to
Seekingalpha · 13h ago
LITE, NOV among premarket losers
ProPhase Labs (PRPH) -23% after pricing equity offering.Neovasc (NVCN) -18%.Biohaven Pharmaceutical (BHVN) -13%.Yield10 Bioscience (YTEN) -12%.Technical Communications (TCCO) -10% after receiving delisting notice from Nasdaq.InVivo Therapeutics (NVIV) -8%....
Seekingalpha · 14h ago
DJ Biohaven Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 16h ago
DJ Biohaven Pharma Price Target Cut to $111.00/Share From $121.00 by HC Wainwright & Co.
Dow Jones · 16h ago
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
, /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season. The first race of the season with Cody behind the whee...
PR Newswire - PRF · 1d ago
BRIEF-Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
reuters.com · 1d ago
Cramer Advises Viewers On Autodesk, Inseego And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Autodesk, Inc. (NASDAQ: ADSK) is one of the best run companies in the world. He thinks it's a buy.
Benzinga · 01/08 12:11
Biohaven acquires Kleo Pharma and licenses platform technology from Yale University
Biohaven Pharmaceutical (BHVN) acquires remaining 58% interest of Kleo Pharmaceuticals and executed an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab.In
Seekingalpha · 01/07 12:52
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ("Kleo") that it did not previously own and the execution ...
PR Newswire - PRF · 01/07 12:30
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
PR Newswire · 01/07 12:30
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
, /PRNewswire/ --Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona. Biohaven joins Eurasia Motorsports and BAM ...
PR Newswire - PRF · 01/05 15:00
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
Zacks · 01/05 14:08
Enrollment underway in Biohaven's late-stage study of troriluzole in obsessive-compulsive disorder
Biohaven Pharmaceutical (BHVN) has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder ((OCD)).The company plans to enroll ~600
Seekingalpha · 01/04 12:46
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial
Benzinga · 01/04 12:32
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
, /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive di...
PR Newswire - PRF · 01/04 12:30
Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
Zacks · 12/30/2020 13:49
Webull provides a variety of real-time BHVN stock news. You can receive the latest news about Biohaven Pharma through multiple platforms. This information may help you make smarter investment decisions.
About BHVN
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.
More